Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of T Cell Receptor-Redirected T Cell Infusion For Prevention of Hepatocellular Carcinoma Recurrence in Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma Post Liver Transplantation

Next Previous
Trial Profile

A Phase I Study of T Cell Receptor-Redirected T Cell Infusion For Prevention of Hepatocellular Carcinoma Recurrence in Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma Post Liver Transplantation

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 27 Jun 2022 Number of treatment arms have been increased from 1 to 2 by the addition of No intervention and TCR-T (at crossover) arm. Study design is changed from single group assignment to sequential. Upper age limit is increased from 65 years to 75 years, thus including elderly patients also.
  • 01 Jun 2018 New trial record
  • 27 May 2018 According to a Lion TCR media release,the company have raised US$ 20 million in its Series A financing round.The proceeds from this fund raising will be primarily used to advance its on-going clinical trials of LioCyx, including this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top